Optimising thromboembolic and stroke prevention in pharmacist-managed oral anticoagulotherapy
- Conditions
- Circulatory SystemStrokeThromboembolism and stroke
- Registration Number
- ISRCTN76463647
- Lead Sponsor
- Cité de la Santé de Laval (Canada)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 500
1. The patient is referred to the Pharmacy Managed Anticoagulation Service (PMAS) with a prescription of warfarin for at least six months
2. The patient is aged 18 years and older, either sex
3. The patient agrees to go to the Cité de la Santé de Laval, the Centre Hospitalier Ambulatoire Régional de Laval, or one of the four Laval Centre Local de Services Communautaire for blood drawing during participation in the study (six months)
4. The patient lives in the Laval area
5. The patient is able to read and speak French or English
6. The patient agrees to participate in the study and has signed the informed consent form
7. The patient's treating physician has agreed to participate and has signed the informed consent form
8. It is expected that the patient will be transferred to the treating physician
1. The patient participates to another study
2. The patient is referred to the PMAS for a pre-admission
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of time spent within the target INR range.
- Secondary Outcome Measures
Name Time Method 1. Incidence and severity of major thromboembolic and haemorrhagic events<br>2. Health-related quality of life<br>3. Direct medical-care costs